[1] Senzolo M, Garcia-Tsao G, García-Pagán J. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol,2021.
[2] 中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年,上海). 中华肝脏病杂志,2020,28:999-1007.
[3] 黄晓铨, 倪礼爰, 姜思雨,等. 门静脉血栓影响内镜治疗预防乙型肝炎肝硬化食管胃静脉曲张破裂再出血的疗效. 中华肝脏病杂志,2020,28:747-752.
[4] Driever EG, von Meijenfeldt FA, Adelmeijer J, et al. Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus. Hepatology. 2021.
[5] Maruyama H, Okugawa H, Takahashi M, et al. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol,2013,108:568-574.
[6] Turon F, Driever EG, Baiges A, et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol,2021.
[7] Xu X, Guo X, Stefano VD, et al. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatol Int,2019,13:468-481.
[8] Nery F, Correia S, Macedo C, et al. Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study. Aliment Pharmacol Ther. 2019,49:582-588.
[9] La Mura V, Tripodi A, Tosetti G, et al. Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis. Liver Int,2016,36:1322-1330.
[10] Huang X, Fan X, Zhang R, et al. Systemic inflammation and portal vein thrombosis in cirrhotic patients with gastroesophageal varices. European Journal of Gastroenterology & Hepatology, 2020,32.
[11] Carnevale R, Raparelli V, Nocella C, et al. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. J Hepatol,2017,67:950-956.
[12] Zhang Y, Xu BY, Wang XB, et al. Prevalence and Clinical Significance of Portal Vein Thrombosis in Patients With Cirrhosis and Acute Decompensation. Clin Gastroenterol Hepatol,2020,18:2564-2572.e1.
[13] Stine JG, Shah NL, Argo CK, et al. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transpl,2015,21 21:1016-1021.
[14] Luca A, Caruso S, Milazzo M, et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology,2012,265:124-132.
[15] Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study. Hepatology,2015,61:660-667.
[16] Pettinari, Vukotic, Stefanescu, et al. Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis. Am J Gastroenterol,2019,114:258-266.
[17] Dong S, Qi H, Li Y. A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat? Hepatol Int, 2021, 15:1356-1375.
[18] Rodrigues SG, Sixt S, Abraldes JG, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther. 2019,49:20-30.
[19] Lv Y, Qi X, He C, et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut,2018,67:2156-2168. |
